Non Muscle Invasive Bladder Cancer Pipeline

DelveInsight’s, “Non Muscle Invasive Bladder Cancer Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Non Muscle Invasive Bladder Cancer Disease Understanding

Non Muscle Invasive Bladder Cancer Overview

Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer in which the tumor remains confined to the inner lining of the bladder and does not invade the muscular wall. NMIBC includes stages Ta, T1, and carcinoma in situ (CIS), and is characterized by abnormal growth of urothelial cells within the bladder mucosa. Although the disease is generally considered less aggressive than muscle-invasive bladder cancer, it has a strong tendency for recurrence and progression in some patients, making continuous monitoring important.

The pathophysiology of non-muscle invasive bladder cancer (NMIBC) involves genetic and molecular alterations in urothelial cells that lead to uncontrolled cell growth within the bladder lining. Mutations in pathways regulating cell proliferation and survival, such as FGFR3 and RAS signaling, are commonly associated with low-grade tumors, while alterations in TP53 and RB1 are linked to more aggressive disease. These changes promote abnormal urothelial cell proliferation, tumor formation, and the potential for recurrence and progression.

Non-muscle invasive bladder cancer (NMIBC) is associated with genetic changes and exposure to carcinogens that damage the bladder lining. Smoking is the major risk factor, while chemical exposure, chronic bladder irritation, infections, radiation, and genetic susceptibility can also contribute to abnormal urothelial cell growth and tumor development.

Diagnosis of non-muscle invasive bladder cancer (NMIBC) typically involves cystoscopy, which allows direct visualization of the bladder lining, along with urine cytology to detect abnormal cancer cells. Imaging techniques and transurethral resection of bladder tumor (TURBT) are also used to confirm the diagnosis, determine tumor stage and grade, and evaluate the extent of disease involvement within the bladder.

Treatment of non-muscle invasive bladder cancer (NMIBC) usually begins with transurethral resection of the bladder tumor (TURBT), a procedure used to remove visible tumors from the bladder lining and confirm the diagnosis. Following TURBT, patients often receive intravesical therapy, in which therapeutic agents are delivered directly into the bladder to reduce the risk of recurrence and disease progression. Bacillus Calmette–Guérin (BCG) immunotherapy is commonly used for intermediate- and high-risk NMIBC, while intravesical chemotherapy may also be used in selected patients. Treatment choice generally depends on tumor stage, grade, and the patient’s overall risk profile.

“Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2026” report by DelveInsight outlays comprehensive insights of the present scenario and growth prospects across the indication. A detailed picture of the Non Muscle Invasive Bladder Cancer pipeline landscape is provided, which includes the disease overview and Non Muscle Invasive Bladder Cancer treatment guidelines. The assessment part of the report embraces in-depth Non Muscle Invasive Bladder Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, a detailed description of the drug is given, which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non Muscle Invasive Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Non Muscle Invasive Bladder Cancer Pipeline Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Non Muscle Invasive Bladder Cancer R&D.
• The therapies under development are focused on novel approaches to treat/improve Non Muscle Invasive Bladder Cancer.

Non Muscle Invasive Bladder Cancer Emerging Drugs Analysis

This segment of the Non Muscle Invasive Bladder Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase II, Phase I, preclinical, and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Non Muscle Invasive Bladder Cancer Emerging Drugs

Cretostimogene grenadenorepvec: CG Oncology

Cretostimogene grenadenorepvec is an oncolytic immunotherapy designed to selectively replicate in and destroy bladder cancer cells while also stimulating anti-tumor immune responses. The therapy is engineered with an E2F-1 promoter to target tumor cells with altered Rb-E2F pathways and includes the GM-CSF gene to enhance immune activation. Viral replication causes tumor cell lysis and releases tumor antigens and GM-CSF, helping trigger a sustained immune response against bladder cancer. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

FGFR3 (TYRA-300): Tyra Biosciences, Inc.

FGFR3 (TYRA-300) is Tyra Biosciences’ lead precision medicine program stemming from its in-house SNÅP platform. TYRA-300 is an investigational oral FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasia, including achondroplasia and hypochondroplasia. In oncology, TYRA-300 is being evaluated in metastatic urothelial cancer (mUC) and intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

MK-3120: Merck & Co., Inc.

MK-3120 is an investigational therapy for bladder cancer, including non-muscle invasive bladder cancer (NMIBC). MK-3120 is a Nectin-4-targeting antibody-drug conjugate (ADC) that carries a topoisomerase I (topo I) inhibitor payload. The drug is designed to specifically bind to Nectin-4, a protein highly expressed on bladder cancer cells. After binding to the tumor cell, the ADC is internalized and releases its topo I inhibitor payload inside the cancer cell, leading to DNA damage, disruption of DNA replication, and ultimately cancer cell death. By selectively targeting Nectin-4–expressing tumor cells, MK-3120 aims to deliver potent anti-cancer activity while limiting exposure to normal tissues. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

AU-011: Aura Biosciences

AU-011 is a first-in-class virus-like drug conjugate (VDC) being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). The therapy is designed to selectively target and destroy cancer cells while sparing healthy tissue. AU-011 binds to heparan sulfate proteoglycans (HSPGs), which are overexpressed on bladder cancer cells, allowing selective tumor targeting. After binding to the tumor cells, the drug is activated by light, leading to rapid disruption of the cancer cell membrane and acute tumor cell death. This process also promotes immunogenic cell death, releasing tumor antigens that may stimulate a systemic anti-tumor immune response and generate longer-term immunity against the cancer. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

Further product details are provided in the report.

Non Muscle Invasive Bladder Cancer Drug Therapeutic Assessment

This segment of the report provides insights about the different Non Muscle Invasive Bladder Cancer drugs segregated based on the following parameters that define the scope of the report.

Major Non Muscle Invasive Bladder Cancer Players in Non Muscle Invasive Bladder Cancer  

There are approximately 20+ key companies developing therapies for Non Muscle Invasive Bladder Cancer. The companies with drug candidates in the most advanced stage, i.e., Phase III, include CG Oncology and others.

Non Muscle Invasive Bladder Cancer Clinical Trial Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development, including:

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Preclinical and discovery-stage candidates
• Discontinued and inactive candidates

Non Muscle Invasive Bladder Cancer Drug Route of Administration

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by route of administration. Products have been categorized under various ROAs such as:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Non Muscle Invasive Bladder Cancer Product Molecule Type

Products have been categorized under various molecule types such as:

Oligonucleotide
Peptide
Small molecule

Non Muscle Invasive Bladder Cancer Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Non Muscle Invasive Bladder Cancer Clinical Trial Activities

The Non Muscle Invasive Bladder Cancer Pipeline report provides insights into Non Muscle Invasive Bladder Cancer Clinical Trial within Phase II, Phase I, preclinical, and discovery stages. It also analyzes Non Muscle Invasive Bladder Cancer therapeutic drugs and the key players involved in developing these drugs.

Non Muscle Invasive Bladder Cancer Pipeline Development Activities

The Non Muscle Invasive Bladder Cancer Clinical Trials analysis report covers detailed information on collaborations, acquisitions and mergers, licensing, along with a thorough therapeutic assessment of emerging Non Muscle Invasive Bladder Cancer drugs.

Non Muscle Invasive Bladder Cancer Pipeline Report Insights

• Non Muscle Invasive Bladder Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Non Muscle Invasive Bladder Cancer Pipeline Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive Drugs Assessment
• Unmet Needs

Key Questions Answered In The Non Muscle Invasive Bladder Cancer Pipeline Report

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Non Muscle Invasive Bladder Cancer drugs?
• How many Non Muscle Invasive Bladder Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage and late-stage development for the treatment of Non Muscle Invasive Bladder Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), mergers and acquisitions, and licensing activities related to the Non Muscle Invasive Bladder Cancer therapeutics?
• What are the recent trends, drug types, and novel technologies developed to overcome the limitations of existing therapies?
• What are the clinical studies going on for Non Muscle Invasive Bladder Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Non Muscle Invasive Bladder Cancer Key Companies

• CG Oncology
• Tyra Biosciences, Inc.
• Merck & Co., Inc.
• Aura Biosciences
• Protara Therapeutics
• Pfizer
• SURGE
• Jiangsu Simcere Pharmaceutical Co., Ltd.
• Prokarium Ltd.
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Shanghai Hengrui Pharmaceutical Co., Ltd.
• RemeGen Co., Ltd.

Non Muscle Invasive Bladder Cancer Key Products

• Cretostimogene grenadenorepvec
• FGFR3 (TYRA-300)
• MK-3120
• AU-011
• TARA-002
• PF-08052667
• STM-416
• SIM0237
• ZH9
• HS-10566
• SHR-2005
• Sacituzumab tirumotecan